Core Insights - Zhejiang province is experiencing a significant transformation in its technology innovation narrative, highlighted by the emergence of the "Hangzhou Six Little Dragons" and a focus on nurturing more tech-driven enterprises [1][3] Group 1: Technology Innovation and Growth - The "Hangzhou Six Little Dragons" have gained recognition, with three of these companies initiating their listing processes, showcasing a new growth trajectory for Chinese tech firms amid a technological revolution [1][2] - In the AR industry, Lingban Technology's Rokid Glasses sold 40,000 units within five days of pre-sale, doubling the sales of AI glasses in China for the first half of the year [2] - Zhejiang's AI core industry generated revenues of 494.4 billion yuan, reflecting a 22% year-on-year growth, with R&D expenses increasing by 14% [2] Group 2: Policy and Support Mechanisms - The Zhejiang government is actively fostering an environment for tech innovation by implementing various support measures, including a "sailing action" for 96 selected tech enterprises, providing policy support and expert guidance [3][4] - The province is promoting collaborative models such as "use first, transfer later" and "open licensing" to accelerate the commercialization of patents [3] - A new insurance scheme for technology transfer costs has been introduced, providing financial support for startups in the AI sector [5] Group 3: Future Development Plans - Zhejiang aims to cultivate a gradient system of quality enterprises, from small tech firms to world-class companies, as part of its 2025-2027 action plan [5][6] - The province's goal is to increase total innovation investment to over 800 billion yuan by 2026, with a research and development intensity target of 3.35% [6] - The emphasis on creating a favorable innovation ecosystem is expected to enhance Zhejiang's competitiveness and attract more talent and investment [4][6]

（央视财经《经济信息联播》）明年是"十五五"规划的开局之年，财政政策将聚焦哪些关键领域精准发 力？ 中国财政科学研究院院长 杨志勇：我们现在要去充分挖掘大国的经济潜能。我们有超大的国内市场， 如果国内市场是分割的话，全国统一大市场的优势就没有发挥出来。所以我们要去改革，我们要规范税 收优惠、财政补贴政策，要通过各个方面的改革，把市场的优势、潜能充分挖掘出来。 此外，在加快培育壮大新动能与保障民生上，财政资金将有力支持科技创新和产业创新深度融合。同 时，切实加强民生保障，促进居民就业增收，支持办好人民满意的教育，提高医疗卫生服务保障水平， 完善社会保障体系，在满足民生需求中拓展发展空间。 会议明确，2026年继续实施更加积极的财政政策，在"加力"和"增效"两个维度上协同发力。在支出力度 上，扩大财政支出盘子，确保必要支出力度。同时，优化政府债券工具组合，更好发挥债券效益。提高 转移支付资金效能。持续优化支出结构，强化重点领域保障。 粤开证券首席经济学家 研究院院长 罗志恒：赤字规模、专项债的规模，以及超长期特别国债，共同构 成的当年新增债务规模可能会进一步增加，以支持更大力度的支出强度。最后会转化成为企业居民的 ...

人才与平台，是驱动科技创新的核心双翼。为赋能"十五五"期间产业跨越发展，大会期间，广药集团还 举行了科技委员会主任、战略专家顾问、首席专家顾问、资深专家顾问的聘任仪式，包括3名院士在内 的超30名专家为广药集团"科技创新大脑"赋能，助力集团建设一个创新动能更澎湃的科技新高地。 除了引进外部"智囊团"，广药集团还大力整合科研体系资源，积极构建覆盖全产业链、面向未来的科研 与转化支柱体系，已打造以七大创新研发平台为核心的创新平台体系，包括中医药创新平台、化学药创 新平台、生物药创新平台、高端营养创新平台、核医药创新平台、动物保健创新平台、医疗器械创新平 台，进一步夯实科技创新策源基础。 作为广东省、广州市生物医药健康产业"链主"企业，广药集团已发展为首家以中医药为主业的世界500 强企业。 "我们希望通过科技创新大会这一平台，让全球合作伙伴、客户及产业链上下游了解，广药集团正加速 转型升级为一家科技型、创新型企业集团。"广药集团党委书记、董事长李小军在致辞中表示，"十五 五"时期是广药集团实现跨越式发展的黄金窗口，广药集团将始终锚定"现代化、数字化、科技化、国际 化"的四化方向，坚定不移抓住科技创新这个"牛鼻子" ...

Group 1 - China's technological innovation capabilities have steadily improved, showcasing significant breakthroughs and achievements in various fields, particularly in space and deep-sea exploration [1][3] - The EAST facility in Anhui achieved a world record of 1 million degrees Celsius plasma maintained for 1066 seconds, marking a major leap in fusion energy research [1] - The Chang'e 6 mission successfully returned the first batch of lunar samples, contributing to the understanding of lunar soil and its cosmic secrets [3] Group 2 - Chinese scientists are making strides in deep-sea exploration, completing manned missions to the Arctic and initiating the UN's "Decade of Ocean Science" global deep-sea exploration plan [4] - Significant advancements in basic research include evidence supporting Lamarckian evolution and breakthroughs in quantum technology, enhancing the understanding of quantum mechanics [6][8] - The development of ultra-high precision measurement techniques in neutrino experiments and the discovery of over 1170 pulsars by the FAST telescope highlight the progress in fundamental science [10] Group 3 - The AI sector in China is evolving, with advancements enabling AI to transition from virtual applications to real-world capabilities, exemplified by humanoid robots that can adapt to physical challenges [11] - The achievements in various scientific fields reflect China's transition from following to leading in technology innovation, contributing to the nation's strength and confidence in future endeavors [13]

中新网杭州12月28日电(张煜欢)在浙江的发展之路上，有一抹色彩温柔而坚定，有一股力量细腻而磅 礴。从实验室里的潜心钻研，到绿水青山间的匠心运营；从数字经济浪潮中的奋勇弄潮，到文化传承创 新中的默默守护……无数浙江女性，将个人的智慧、梦想与汗水融入这片热土的发展脉动。 岁末年终，回望浙江的先行探索之路，那些闪耀着女性光芒的故事与实践，恰是这幅高质量发展图景中 最动人的注脚。她们用各自领域的默默耕耘，共同回答着一个问题：先行之路，何以成章？ 2025年浙 由浙江省妇联主办的浙江省巾帼创新创业大赛自2023年启动以来已成功举办三届，累计8个项目与城西 科技大走廊签约落地，3个项目与嘉兴市签约落地，5个项目与温州市签约落地。获奖项目和选手获最高 达300万元的信贷授信。大赛不仅为无数女性提供了展示才华的平台，更链接了资本、技术、政策等多 方资源，让一颗颗科创种子得以生根发芽、茁壮成长。 近年来，浙江省妇联还联合浙江省科技厅出台《关于鼓励和支持女性科技人才更好发挥作用的若干措 施》，在加大对女性科技人才培养支持力度、支持孕哺期女性科技人才科研等方面取得突破，"女科技 工作者+女企业家创新联合体"的模式，更将智慧火花直 ...

中国青年报客户端讯（中青报·中青网记者 林洁）12月27日，广药集团科技创新大会在广州举行。广药 集团宣布，"十五五"时期拟投入100亿元至150亿元研发费用，加大新药研发力度，打造科技创新型企 业，通过建立健全科技创新的容错机制，优化重大项目决策机制，以更大力度推进科技创新布局。 广药集团 七大创新平台获授旗。主办方供图 同时，广药集团将设立广药资本运营公司，加强资本运作，持续撬动社会资本扩容增效。"十五五"期间 预计研发投入100亿元至150亿元；产业投资与并购200亿元至300亿元，聚合创新生态。广药集团还将携 手大院大所共建高水平联合实验室和创新研究院，联动上下游企业，构建全产业链创新生态，提升科技 成果转化效能。 广药集团将整合科研体系资源，构建覆盖全产业链、面向未来的科研与转化支柱体系。广药集团已打造 以七大创新研发平台为核心的创新平台体系，包括中医药创新平台、化学药创新平台、生物药创新平 台、高端营养创新平台、核医药创新平台、动物保健创新平台、医疗器械创新平台。 当天，广药集团逾20个合作项目进行签约，包括在核医药、动物保健业务等新赛道加速布局。广药集团 拥有超200项在研项目，涵盖恶性肿瘤、慢 ...

Group 1 - The core activity involved over 50 young pioneers from Haokai Bridge Primary School participating in a research and study event organized by the Youth League Committee of Lingwu City and the local town committee [1][3] - The event included learning about traditional culture and technology innovation, with activities such as understanding the production and sound principles of the Kou Xian musical instrument and exploring the local grass weaving industry [3][5] - The initiative aims to guide young pioneers in experiencing the charm of traditional culture and technological advancements while visiting local industry developments [5][6] Group 2 - The Youth League Committee of Lingwu City has been developing a distinctive youth activity brand since 2025, focusing on local development and creating a "one town, one product" model [5] - Various themed research and study activities have been organized by different town committees, such as the "Caring Science Popularization Vegetable Garden" and "Caring Laundry Room" in Majiatan Town [5] - The Lingwu City Committee plans to promote regular youth research and study practices across all towns, encouraging youth to learn and grow through practical experiences [6]

Core Viewpoint - Guangzhou Pharmaceutical Group is accelerating its innovation transformation to overcome operational challenges and aims to invest significantly in research and development as well as industry acquisitions during the 14th Five-Year Plan period [1][5]. Group 1: Innovation Strategy - The company plans to invest between 10 billion to 15 billion yuan in R&D and 20 billion to 30 billion yuan in industrial investments and acquisitions during the 14th Five-Year Plan [1]. - The management emphasizes the need for a dual approach of "self-research + acquisitions" to drive innovation in the pharmaceutical sector [5]. - The company aims to achieve best-in-class status in certain fields and is prepared for a long-term commitment to innovation despite the inherent risks and challenges [5]. Group 2: Business Performance - The major revenue source for Guangzhou Pharmaceutical's listed company platform, Baiyunshan, is the large commercial sector, which generated 29 billion yuan in revenue in the first half of 2025, accounting for nearly 70% of total revenue [2]. - The health sector follows with a revenue of 7.02 billion yuan and a gross margin of 44.67%, while the large pharmaceutical sector generated 5.24 billion yuan with a gross margin of 49.71% [2]. - The performance of the health and pharmaceutical sectors has been sluggish due to increasing competition in the beverage industry and ongoing drug procurement policies [4]. Group 3: Challenges and Market Dynamics - Traditional pharmaceutical companies that have successfully transitioned to innovation have seen growth in sales and licensing revenues, contrasting with traditional Chinese medicine companies facing challenges such as insufficient innovation capacity and aging product structures [5]. - Baiyunshan's R&D investment was only 828 million yuan in 2024, representing a low proportion of 4.26% of the company's revenue, indicating a need for increased focus on innovation [5].

Group 1 - China's technological innovation capabilities have steadily improved, showcasing a series of impressive achievements and breakthroughs in 2025 [1] - The EAST facility in Anhui achieved a world record of 1 billion degrees Celsius plasma for 1066 seconds, marking a significant leap in fusion energy research [5] - The Chinese space station has entered a phase of regular operation, serving as a home for astronauts and a laboratory for groundbreaking experiments, including a new record of 3100 degrees Celsius in its "alchemy furnace" [9] Group 2 - Chinese scientists are making significant strides in fundamental research, with breakthroughs such as molecular-level evidence for Lamarckian evolution and advancements in quantum technology [13] - Major scientific facilities in China have delivered impressive results, including the discovery of over 1170 pulsars by the FAST telescope and improved measurements of solar neutrino oscillation parameters [16] - The development of artificial intelligence in China has progressed to a new stage, with AI systems evolving from language processing to understanding and manipulating the physical world [19]

科技创新是医药健康产业发展的核心引擎。12月27日，2025广药集团科技创新大会在广州召开，吹 响了打造医药健康创新型企业的奋进号角。本次大会以"创新转型 开放共赢"为主题，汇聚顶尖院士、 行业翘楚以及合作伙伴，共商医药健康产业创新大计，向世界传递广药集团"科技引领、创新引领"的发 展理念，聚力构建开放共赢的创新生态，以新质生产力擘画高质量发展新蓝图。 钟南山、饶子和、魏于全、马骏、张亚平、曾木圣、朱健康、周大旺等院士和全国医药健康领域的 专家学者齐聚大会，全国政协常委、湖南省政协副主席、教授张灼华，广州市副市长江智涛，广东省工 业和信息化厅党组成员陈绩以及广东省、广州市相关领导，广药集团合作伙伴，广药集团党委书记、董 事长李小军，党委副书记、副董事长、总经理陈杰辉等出席大会。 "十五五"广药集团打造科技创新型企业 人才与平台，是驱动科技创新的核心双翼。为赋能"十五五"期间产业跨越发展，大会期间，广药集 团还举行了科技委员会主任、战略专家顾问、首席专家顾问、资深专家顾问的聘任仪式，包括3名院士 在内的超30名专家为广药集团"科技创新大脑"赋能，助力集团建设一个创新动能更澎湃的科技新高地。 拟投入研发费用100 ...